Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study

Parkinson's disease has a long prodromal stage with various subclinical motor and non-motor manifestations; however, their evolution in the years before Parkinson's disease is diagnosed is unclear. We traced the evolution of early motor and non-motor manifestations of synucleinopathy from...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Brain (London, England : 1878) Ročník 142; číslo 7; s. 2051
Hlavní autoři:	Fereshtehnejad, Seyed-Mohammad, Yao, Chun, Pelletier, Amelie, Montplaisir, Jacques Y, Gagnon, Jean-François, Postuma, Ronald B
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.07.2019
Témata:	Aged Case-Control Studies Disease Progression Female Humans Lewy Body Disease - complications Lewy Body Disease - diagnosis Longitudinal Studies Male Middle Aged Parkinson Disease - complications Parkinson Disease - diagnosis Prodromal Symptoms Prospective Studies REM Sleep Behavior Disorder - complications Time Factors prodromal stage rapid-eye-movement (REM) sleep behaviour disorder (RBD) evolution parkinsonism
ISSN:	1460-2156, 1460-2156
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Parkinson's disease has a long prodromal stage with various subclinical motor and non-motor manifestations; however, their evolution in the years before Parkinson's disease is diagnosed is unclear. We traced the evolution of early motor and non-motor manifestations of synucleinopathy from the stage of idiopathic rapid eye movement (REM) sleep behaviour disorder until defined neurodegenerative disease. During 2004-16, we recruited and then annually followed 154 polysomnography-proven patients with idiopathic REM sleep behaviour disorder, of whom 55 phenoconverted to defined parkinsonism or dementia. Longitudinal data on multiple prodromal features, including the Unified Parkinson's Disease Rating Scale parts I-III, quantitative motor tests, olfaction, colour vision, cognition, and autonomic functions were gathered annually (average = five follow-up visits, range: 2-12 years). The same measures were also assessed in 102 age- and sex-matched healthy control subjects. By looking backward from the time of dementia or parkinsonism diagnosis, we examined trajectories of each prodromal feature using mixed effect models. Based on analysis, olfactory loss was first to develop, with predicted onset >20 years before phenoconversion. This was followed by impaired colour vision, constipation, and erectile dysfunction, starting 10-16 years prior to phenoconversion. At 7-9 years before phenoconversion, slight urinary dysfunction and subtle cognitive decline could be detected. Among motor symptoms altered handwriting, turning in bed, walking, salivation, speech, and facial expression began to be disrupted starting 7-11 years prior to parkinsonism diagnosis, but remained mild until soon before phenoconversion. Motor examination abnormalities began 5-7 years before phenoconversion, with the alternate tap test having the longest interval (8 years before phenoconversion). Among cardinal motor phenotypes, bradykinesia appeared first, ∼5-6 years prior to phenoconversion, followed by rigidity (Year -3) and tremor (Year -2). With direct prospective evaluation of an idiopathic REM sleep behaviour disorder cohort during phenoconversion, we documented an evolution of prodromal manifestations similar to that predicted by pathological staging models, with predicted prodromal intervals as long as 20 years.
AbstractList	Parkinson's disease has a long prodromal stage with various subclinical motor and non-motor manifestations; however, their evolution in the years before Parkinson's disease is diagnosed is unclear. We traced the evolution of early motor and non-motor manifestations of synucleinopathy from the stage of idiopathic rapid eye movement (REM) sleep behaviour disorder until defined neurodegenerative disease. During 2004-16, we recruited and then annually followed 154 polysomnography-proven patients with idiopathic REM sleep behaviour disorder, of whom 55 phenoconverted to defined parkinsonism or dementia. Longitudinal data on multiple prodromal features, including the Unified Parkinson's Disease Rating Scale parts I-III, quantitative motor tests, olfaction, colour vision, cognition, and autonomic functions were gathered annually (average = five follow-up visits, range: 2-12 years). The same measures were also assessed in 102 age- and sex-matched healthy control subjects. By looking backward from the time of dementia or parkinsonism diagnosis, we examined trajectories of each prodromal feature using mixed effect models. Based on analysis, olfactory loss was first to develop, with predicted onset >20 years before phenoconversion. This was followed by impaired colour vision, constipation, and erectile dysfunction, starting 10-16 years prior to phenoconversion. At 7-9 years before phenoconversion, slight urinary dysfunction and subtle cognitive decline could be detected. Among motor symptoms altered handwriting, turning in bed, walking, salivation, speech, and facial expression began to be disrupted starting 7-11 years prior to parkinsonism diagnosis, but remained mild until soon before phenoconversion. Motor examination abnormalities began 5-7 years before phenoconversion, with the alternate tap test having the longest interval (8 years before phenoconversion). Among cardinal motor phenotypes, bradykinesia appeared first, ∼5-6 years prior to phenoconversion, followed by rigidity (Year -3) and tremor (Year -2). With direct prospective evaluation of an idiopathic REM sleep behaviour disorder cohort during phenoconversion, we documented an evolution of prodromal manifestations similar to that predicted by pathological staging models, with predicted prodromal intervals as long as 20 years.Parkinson's disease has a long prodromal stage with various subclinical motor and non-motor manifestations; however, their evolution in the years before Parkinson's disease is diagnosed is unclear. We traced the evolution of early motor and non-motor manifestations of synucleinopathy from the stage of idiopathic rapid eye movement (REM) sleep behaviour disorder until defined neurodegenerative disease. During 2004-16, we recruited and then annually followed 154 polysomnography-proven patients with idiopathic REM sleep behaviour disorder, of whom 55 phenoconverted to defined parkinsonism or dementia. Longitudinal data on multiple prodromal features, including the Unified Parkinson's Disease Rating Scale parts I-III, quantitative motor tests, olfaction, colour vision, cognition, and autonomic functions were gathered annually (average = five follow-up visits, range: 2-12 years). The same measures were also assessed in 102 age- and sex-matched healthy control subjects. By looking backward from the time of dementia or parkinsonism diagnosis, we examined trajectories of each prodromal feature using mixed effect models. Based on analysis, olfactory loss was first to develop, with predicted onset >20 years before phenoconversion. This was followed by impaired colour vision, constipation, and erectile dysfunction, starting 10-16 years prior to phenoconversion. At 7-9 years before phenoconversion, slight urinary dysfunction and subtle cognitive decline could be detected. Among motor symptoms altered handwriting, turning in bed, walking, salivation, speech, and facial expression began to be disrupted starting 7-11 years prior to parkinsonism diagnosis, but remained mild until soon before phenoconversion. Motor examination abnormalities began 5-7 years before phenoconversion, with the alternate tap test having the longest interval (8 years before phenoconversion). Among cardinal motor phenotypes, bradykinesia appeared first, ∼5-6 years prior to phenoconversion, followed by rigidity (Year -3) and tremor (Year -2). With direct prospective evaluation of an idiopathic REM sleep behaviour disorder cohort during phenoconversion, we documented an evolution of prodromal manifestations similar to that predicted by pathological staging models, with predicted prodromal intervals as long as 20 years. Parkinson's disease has a long prodromal stage with various subclinical motor and non-motor manifestations; however, their evolution in the years before Parkinson's disease is diagnosed is unclear. We traced the evolution of early motor and non-motor manifestations of synucleinopathy from the stage of idiopathic rapid eye movement (REM) sleep behaviour disorder until defined neurodegenerative disease. During 2004-16, we recruited and then annually followed 154 polysomnography-proven patients with idiopathic REM sleep behaviour disorder, of whom 55 phenoconverted to defined parkinsonism or dementia. Longitudinal data on multiple prodromal features, including the Unified Parkinson's Disease Rating Scale parts I-III, quantitative motor tests, olfaction, colour vision, cognition, and autonomic functions were gathered annually (average = five follow-up visits, range: 2-12 years). The same measures were also assessed in 102 age- and sex-matched healthy control subjects. By looking backward from the time of dementia or parkinsonism diagnosis, we examined trajectories of each prodromal feature using mixed effect models. Based on analysis, olfactory loss was first to develop, with predicted onset >20 years before phenoconversion. This was followed by impaired colour vision, constipation, and erectile dysfunction, starting 10-16 years prior to phenoconversion. At 7-9 years before phenoconversion, slight urinary dysfunction and subtle cognitive decline could be detected. Among motor symptoms altered handwriting, turning in bed, walking, salivation, speech, and facial expression began to be disrupted starting 7-11 years prior to parkinsonism diagnosis, but remained mild until soon before phenoconversion. Motor examination abnormalities began 5-7 years before phenoconversion, with the alternate tap test having the longest interval (8 years before phenoconversion). Among cardinal motor phenotypes, bradykinesia appeared first, ∼5-6 years prior to phenoconversion, followed by rigidity (Year -3) and tremor (Year -2). With direct prospective evaluation of an idiopathic REM sleep behaviour disorder cohort during phenoconversion, we documented an evolution of prodromal manifestations similar to that predicted by pathological staging models, with predicted prodromal intervals as long as 20 years.
Author	Yao, Chun Montplaisir, Jacques Y Fereshtehnejad, Seyed-Mohammad Gagnon, Jean-François Postuma, Ronald B Pelletier, Amelie
Author_xml	– sequence: 1 givenname: Seyed-Mohammad surname: Fereshtehnejad fullname: Fereshtehnejad, Seyed-Mohammad organization: Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden – sequence: 2 givenname: Chun surname: Yao fullname: Yao, Chun organization: Integrated Program in Neuroscience, McGill University, QC, Canada – sequence: 3 givenname: Amelie surname: Pelletier fullname: Pelletier, Amelie organization: Research Institute of the McGill University Health Centre, Montreal General Hospital, Department of Neurology, Montreal, QC, Canada – sequence: 4 givenname: Jacques Y surname: Montplaisir fullname: Montplaisir, Jacques Y organization: Department of Psychiatry, Université de Montréal, Montreal, QC, Canada – sequence: 5 givenname: Jean-François surname: Gagnon fullname: Gagnon, Jean-François organization: Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada – sequence: 6 givenname: Ronald B surname: Postuma fullname: Postuma, Ronald B organization: Centre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Cœur de Montréal, Montréal, QC, Canada
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31111143$$D View this record in MEDLINE/PubMed
BookMark	eNpNUDtPwzAYtFARfcDGjLzBEprPzqNhQ1V5SJVggBFFX-zPwpDYJU5alV9PK4rELXfD3el0YzZw3hFj5xBfQ1zIadWidVPcfAPAERtBksWRgDQb_NNDNg7hI44hkSI7YUMJeyRyxN4Wa1_3nfWOe8NXrdetb7Dmz9h-Whe8uwxc20AYiKPTXFNDrrPIN7Z750vabHnltaVww3EfDytSnV0TD12vt6fs2GAd6OzAE_Z6t3iZP0TLp_vH-e0yUjLLu8hgmqt0J5MKjCIsKJF5LJJZBgXpVBkJaHKTg4Y8FakBhQiajEaVZTMUYsKufnt3C756Cl3Z2KCortGR70MphBRxATO5t14crH3VkC5XrW2w3ZZ_l4gfVORmuA
CitedBy_id	crossref_primary_10_1212_WNL_0000000000200235 crossref_primary_10_3390_nu14235185 crossref_primary_10_1007_s10286_020_00730_0 crossref_primary_10_1212_WNL_0000000000200236 crossref_primary_10_5498_wjp_v12_i9_1127 crossref_primary_10_3233_JPD_230285 crossref_primary_10_1002_mds_30006 crossref_primary_10_1002_mds_30126 crossref_primary_10_1136_jnnp_2022_330048 crossref_primary_10_1001_jamanetworkopen_2023_38080 crossref_primary_10_1016_S1875_5364_22_60145_6 crossref_primary_10_1111_ene_16101 crossref_primary_10_1212_WNL_0000000000010942 crossref_primary_10_3389_fcell_2021_755254 crossref_primary_10_1002_mds_27869 crossref_primary_10_1038_s41531_024_00751_w crossref_primary_10_1038_s41531_025_00961_w crossref_primary_10_1093_brain_awad325 crossref_primary_10_3389_fnagi_2021_722836 crossref_primary_10_1002_ana_26835 crossref_primary_10_1097_MD_0000000000036985 crossref_primary_10_3233_JPD_202134 crossref_primary_10_3233_JPD_240091 crossref_primary_10_1016_j_ncl_2024_12_004 crossref_primary_10_3389_fneur_2024_1452741 crossref_primary_10_1038_s42003_022_03002_x crossref_primary_10_1002_mdc3_13003 crossref_primary_10_1007_s00702_025_02936_w crossref_primary_10_1109_ACCESS_2025_3604877 crossref_primary_10_1080_14737175_2021_1953984 crossref_primary_10_1212_WNL_0000000000010002 crossref_primary_10_1186_s13041_021_00875_7 crossref_primary_10_3233_JPD_230267 crossref_primary_10_3389_fnins_2025_1600148 crossref_primary_10_3233_JAD_220657 crossref_primary_10_1016_j_parkreldis_2022_04_007 crossref_primary_10_3390_metabo12121222 crossref_primary_10_1002_ana_27166 crossref_primary_10_3389_fneur_2022_831428 crossref_primary_10_1007_s10286_023_00933_1 crossref_primary_10_1016_j_sleep_2023_10_027 crossref_primary_10_1038_s41370_024_00687_6 crossref_primary_10_1016_j_pharmthera_2024_108683 crossref_primary_10_1016_S1474_4422_21_00176_9 crossref_primary_10_1002_mds_29383 crossref_primary_10_3390_jcm14020498 crossref_primary_10_1016_j_neuint_2024_105683 crossref_primary_10_3233_JPD_213039 crossref_primary_10_1177_1877718X251361506 crossref_primary_10_3389_fneur_2021_799017 crossref_primary_10_1038_s41582_021_00486_9 crossref_primary_10_1212_WNL_0000000000209394 crossref_primary_10_3390_molecules30081672 crossref_primary_10_3390_ijms22084286 crossref_primary_10_1136_bmj_2024_080952 crossref_primary_10_1016_j_parkreldis_2024_106982 crossref_primary_10_1093_brain_awab191 crossref_primary_10_1093_sleep_zsae258 crossref_primary_10_1371_journal_pone_0294984 crossref_primary_10_1038_s41531_021_00191_w crossref_primary_10_1212_WNL_0000000000213470 crossref_primary_10_1002_jnr_24779 crossref_primary_10_1002_mds_28637 crossref_primary_10_3233_JPD_223264 crossref_primary_10_3389_fnins_2023_1295344 crossref_primary_10_1002_mds_28636 crossref_primary_10_1002_alz_12411 crossref_primary_10_1016_j_sleep_2024_01_019 crossref_primary_10_1136_bmjno_2025_001215 crossref_primary_10_1080_14737159_2022_2037424 crossref_primary_10_1002_mdc3_13314 crossref_primary_10_1016_j_parkreldis_2020_09_041 crossref_primary_10_1038_s41531_024_00734_x crossref_primary_10_1002_mds_28873 crossref_primary_10_3233_JPD_191759 crossref_primary_10_3389_fnagi_2023_1264143 crossref_primary_10_1002_mds_30171 crossref_primary_10_3389_fneur_2021_677213 crossref_primary_10_1016_j_nbd_2022_105687 crossref_primary_10_1016_j_neuroimage_2025_121012 crossref_primary_10_1016_j_arr_2022_101759 crossref_primary_10_3389_fneur_2025_1555175 crossref_primary_10_3389_fnhum_2021_808734 crossref_primary_10_1002_gps_5703 crossref_primary_10_1371_journal_pone_0258786 crossref_primary_10_1016_S1474_4422_25_00085_7 crossref_primary_10_1016_j_csl_2021_101322 crossref_primary_10_1016_j_heliyon_2023_e17876 crossref_primary_10_1038_s41531_025_00948_7 crossref_primary_10_1007_s10334_023_01081_3 crossref_primary_10_3389_fnagi_2025_1468895 crossref_primary_10_1016_j_jagp_2025_07_014 crossref_primary_10_1002_alz_13716 crossref_primary_10_1016_j_nbd_2019_104700 crossref_primary_10_1038_s41531_024_00817_9 crossref_primary_10_1371_journal_pone_0279927 crossref_primary_10_3389_fnagi_2025_1501640 crossref_primary_10_3233_JPD_230348 crossref_primary_10_1038_s44286_025_00219_5 crossref_primary_10_1038_s41582_022_00686_x crossref_primary_10_3233_JPD_191851 crossref_primary_10_1016_j_tins_2020_05_001 crossref_primary_10_1016_j_jocn_2019_12_029 crossref_primary_10_1093_sleep_zsad198 crossref_primary_10_1002_mds_29503 crossref_primary_10_1002_mds_28777 crossref_primary_10_1002_ana_25962 crossref_primary_10_1002_ana_26811 crossref_primary_10_1016_j_nbd_2021_105601 crossref_primary_10_1212_WNL_0000000000009323 crossref_primary_10_1212_WNL_0000000000011088 crossref_primary_10_3390_ijms24031842 crossref_primary_10_3233_JPD_230350 crossref_primary_10_1186_s40478_024_01782_3 crossref_primary_10_1177_1877718X251359225 crossref_primary_10_1016_j_neuroimage_2023_119908 crossref_primary_10_1002_mdc3_13786 crossref_primary_10_1016_j_parkreldis_2022_07_005 crossref_primary_10_1136_bmjdrc_2022_003036 crossref_primary_10_1080_23279095_2024_2443591 crossref_primary_10_1093_sleep_zsab067 crossref_primary_10_1002_dad2_70044 crossref_primary_10_1016_j_parkreldis_2020_10_003 crossref_primary_10_1016_j_parkreldis_2022_09_007 crossref_primary_10_3390_healthcare13151873 crossref_primary_10_1093_brain_awaa216 crossref_primary_10_1007_s00415_025_12995_4 crossref_primary_10_1111_jsr_14263 crossref_primary_10_1007_s11357_025_01701_x crossref_primary_10_3389_fneur_2025_1631165 crossref_primary_10_1007_s43657_022_00051_4 crossref_primary_10_1038_s41531_025_00942_z crossref_primary_10_3390_toxins13030226 crossref_primary_10_1007_s00415_024_12194_7 crossref_primary_10_3390_biomedicines12102257 crossref_primary_10_1109_TBME_2021_3116935 crossref_primary_10_1177_1877718X251334050 crossref_primary_10_3389_fnagi_2022_861035 crossref_primary_10_1016_j_parkreldis_2022_09_016 crossref_primary_10_1002_mds_29515 crossref_primary_10_1016_j_clinph_2020_04_017 crossref_primary_10_1038_s41591_024_03469_7 crossref_primary_10_3389_fneur_2020_00556 crossref_primary_10_1007_s11357_025_01757_9 crossref_primary_10_1186_s13195_024_01523_7 crossref_primary_10_3233_JPD_202098 crossref_primary_10_3389_fneur_2020_603582 crossref_primary_10_3390_bs11050074 crossref_primary_10_1038_s41583_021_00542_9 crossref_primary_10_1002_mdc3_70333 crossref_primary_10_3390_brainsci12020199 crossref_primary_10_1146_annurev_pathmechdis_031521_034145 crossref_primary_10_1002_dad2_70141 crossref_primary_10_1136_jnnp_2021_328062 crossref_primary_10_3233_JAD_190727 crossref_primary_10_3390_ctn5020013 crossref_primary_10_1016_j_parkreldis_2021_04_001 crossref_primary_10_3389_fpubh_2025_1589512 crossref_primary_10_1016_j_parkreldis_2021_04_007 crossref_primary_10_1093_brain_awab404 crossref_primary_10_3233_JPD_230429 crossref_primary_10_3390_clinpract15030065 crossref_primary_10_1212_WNL_0000000000214108 crossref_primary_10_3233_JPD_191773 crossref_primary_10_1002_mds_29662 crossref_primary_10_1007_s40265_021_01664_1 crossref_primary_10_1007_s00210_019_01715_1 crossref_primary_10_1038_s41531_025_00904_5 crossref_primary_10_1002_mdc3_13073 crossref_primary_10_1016_S1474_4422_19_30355_2 crossref_primary_10_1177_15459683211011238 crossref_primary_10_1111_jgs_19238 crossref_primary_10_3233_JPD_230436 crossref_primary_10_1002_mds_29779 crossref_primary_10_1136_jnnp_2022_329342 crossref_primary_10_1038_s41531_025_01058_0 crossref_primary_10_1016_j_ebiom_2025_105753 crossref_primary_10_1016_j_parkreldis_2021_07_022 crossref_primary_10_1093_ageing_afaf241 crossref_primary_10_1016_j_parkreldis_2024_107042 crossref_primary_10_1016_S0140_6736_21_00218_X crossref_primary_10_1016_j_molmed_2020_01_005 crossref_primary_10_3389_fpsyt_2022_910896 crossref_primary_10_1007_s11910_021_01101_6 crossref_primary_10_1016_j_dsp_2024_104407 crossref_primary_10_1007_s00415_024_12726_1 crossref_primary_10_1016_j_nbd_2023_106369 crossref_primary_10_3233_JPD_212775 crossref_primary_10_3233_JPD_230400 crossref_primary_10_1111_jsr_14228 crossref_primary_10_1016_j_parkreldis_2023_105815 crossref_primary_10_1212_CON_0000000000001154 crossref_primary_10_1007_s10286_025_01121_z crossref_primary_10_1016_j_sleep_2020_01_010 crossref_primary_10_1177_1877718X251329354 crossref_primary_10_3390_bioengineering10080984 crossref_primary_10_1016_j_parkreldis_2021_08_008 crossref_primary_10_3389_fpsyg_2022_1018176 crossref_primary_10_3389_fnagi_2025_1505374 crossref_primary_10_1002_mds_28592 crossref_primary_10_1172_JCI186591 crossref_primary_10_1186_s13195_022_01037_0 crossref_primary_10_1016_j_nbd_2020_104996 crossref_primary_10_1212_WNL_0000000000214037 crossref_primary_10_36290_neu_2025_002 crossref_primary_10_1007_s10072_022_06316_0 crossref_primary_10_3389_fnins_2020_528809 crossref_primary_10_1002_alz_13357 crossref_primary_10_1007_s40120_024_00620_x crossref_primary_10_1002_ana_26085 crossref_primary_10_1016_j_parkreldis_2023_105389 crossref_primary_10_3389_fnins_2022_874349 crossref_primary_10_1038_s41582_019_0215_z crossref_primary_10_1093_brain_awad072 crossref_primary_10_1177_1073858421990000 crossref_primary_10_2147_NSS_S266071 crossref_primary_10_3389_fneur_2024_1386608 crossref_primary_10_3390_ijms21134718 crossref_primary_10_3390_healthcare11243187 crossref_primary_10_1155_2021_2015123 crossref_primary_10_1002_mds_30308 crossref_primary_10_1186_s40035_022_00286_1 crossref_primary_10_1186_s12877_022_03035_1 crossref_primary_10_1212_WNL_0000000000209220 crossref_primary_10_1016_j_arr_2024_102232 crossref_primary_10_1007_s11910_022_01171_0 crossref_primary_10_1111_1460_6984_13025 crossref_primary_10_1212_WNL_0000000000208015 crossref_primary_10_3233_JPD_223201 crossref_primary_10_3233_NRE_210301 crossref_primary_10_1002_mds_28931 crossref_primary_10_1016_j_neubiorev_2023_105479 crossref_primary_10_3389_fneur_2025_1616780 crossref_primary_10_1080_14737175_2020_1676152 crossref_primary_10_1093_brain_awaf003 crossref_primary_10_1002_mdc3_70007 crossref_primary_10_1177_1877718X251327138 crossref_primary_10_1016_j_nbd_2022_105626 crossref_primary_10_1038_s41531_022_00373_0 crossref_primary_10_1002_mdc3_70122 crossref_primary_10_1038_s41591_023_02440_2 crossref_primary_10_1186_s13024_023_00622_7 crossref_primary_10_1007_s00415_025_13080_6 crossref_primary_10_1212_WNL_0000000000208020 crossref_primary_10_1007_s00415_023_12145_8 crossref_primary_10_1038_s41531_023_00598_7 crossref_primary_10_3389_fneur_2020_00610 crossref_primary_10_1002_mds_28006 crossref_primary_10_1038_s41440_024_01829_x
ContentType	Journal Article
Copyright	The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Copyright_xml	– notice: The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/brain/awz111
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1460-2156
ExternalDocumentID	31111143
Genre	Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: Canadian Institutes for Health
GroupedDBID	--- -E4 -~X .2P .I3 .XZ .ZR 0R~ 1TH 23N 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6PF 70D AABZA AACZT AAIMJ AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAVLN AAWTL ABDFA ABEJV ABEUO ABGNP ABIVO ABIXL ABJNI ABKDP ABLJU ABMNT ABNHQ ABNKS ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABXZS ABZBJ ACGFS ACIWK ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGKP ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AELWJ AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ARIXL ATGXG AXUDD AYOIW BAWUL BAYMD BCRHZ BEYMZ BHONS BQDIO BR6 BSWAC BTRTY BVRKM C45 CDBKE CGR COF CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS F5P F9B FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH NPM O9- OAUYM OAWHX OBOKY OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TLC TR2 VVN W8F WH7 WOQ X7H YAYTL YKOAZ YSK YXANX ZKX ~91 7X8 ABUFD
ID	FETCH-LOGICAL-c367t-fa57c53674b1fcea9e4370248619ed5cf31af7f71d17525f1caa1defdac668a22
IEDL.DBID	7X8
ISICitedReferencesCount	280
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000481420100028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1460-2156
IngestDate	Sun Nov 09 11:24:32 EST 2025 Mon Jul 21 06:05:00 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	prodromal stage rapid-eye-movement (REM) sleep behaviour disorder (RBD) evolution parkinsonism
Language	English
License	The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c367t-fa57c53674b1fcea9e4370248619ed5cf31af7f71d17525f1caa1defdac668a22
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://academic.oup.com/brain/article-pdf/142/7/2051/28881208/awz111.pdf
PMID	31111143
PQID	2232091832
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2232091832 pubmed_primary_31111143
PublicationCentury	2000
PublicationDate	2019-07-01
PublicationDateYYYYMMDD	2019-07-01
PublicationDate_xml	– month: 07 year: 2019 text: 2019-07-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Brain (London, England : 1878)
PublicationTitleAlternate	Brain
PublicationYear	2019
References	31505543 - Brain. 2019 Jul 1;142(7):1850-1852
References_xml	– reference: 31505543 - Brain. 2019 Jul 1;142(7):1850-1852
SSID	ssj0014326
Score	2.6787958
Snippet	Parkinson's disease has a long prodromal stage with various subclinical motor and non-motor manifestations; however, their evolution in the years before...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2051
SubjectTerms	Aged Case-Control Studies Disease Progression Female Humans Lewy Body Disease - complications Lewy Body Disease - diagnosis Longitudinal Studies Male Middle Aged Parkinson Disease - complications Parkinson Disease - diagnosis Prodromal Symptoms Prospective Studies REM Sleep Behavior Disorder - complications Time Factors
Title	Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study
URI	https://www.ncbi.nlm.nih.gov/pubmed/31111143 https://www.proquest.com/docview/2232091832
Volume	142
WOSCitedRecordID	wos000481420100028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVhA8Le3mtYkXEWnx0JYeVHqRMNkH9GBSm9qiv97ZZEtPguAl5DIQZiYz37wJuREa2kZqxYwwPguy0LDMZIIBug6J8EAmVU73tScGg3g0SoYu4Va6tsqlTawMtSqkzZG30I156NtQAe8nH8xejbLVVXdCY500fIQyVqvFaFVFCHzPTRe1Gbq2yDW-YxDfyuwBhhYsvjnnv4PLysl0d__7eXtkx8FL-lDrwz5Z0_kB2eq7AvoheevMna7RwlBrPafFOxLY4edqDuy2pK5mQyFXVFXZwzFQm6-lPb34ollhGw_vKFjy5aAmrdbUHpGXbuf58Ym5CwtM-pGYMQOhkCG-BhlHiUGiA1_YLWcYVmkVSuNzQCEKrhBleKHhEoArbRTIKIrB847JRl7k-pTQSGRxEiiuDIacGNMlvowD8IJQI8AMFTTJ9ZJxKWqwLUtArovPMl2xrklOau6nk3rVRupbi45yPPsD9TnZRjST1L20F6Rh8P_Vl2RTzmfjcnpVqQY-B8P-D6R-xiE
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evolution+of+prodromal+Parkinson%27s+disease+and+dementia+with+Lewy+bodies%3A+a+prospective+study&rft.jtitle=Brain+%28London%2C+England+%3A+1878%29&rft.au=Fereshtehnejad%2C+Seyed-Mohammad&rft.au=Yao%2C+Chun&rft.au=Pelletier%2C+Amelie&rft.au=Montplaisir%2C+Jacques+Y&rft.date=2019-07-01&rft.issn=1460-2156&rft.eissn=1460-2156&rft.volume=142&rft.issue=7&rft.spage=2051&rft_id=info:doi/10.1093%2Fbrain%2Fawz111&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2156&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2156&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2156&client=summon